Brensocatib - The New Bronchiectasis Drug

Many of us in the bronchiectasis community have followed the development of brensocatib for years — from the promising results of the Phase 2 WILLOW trial to the eagerly awaited findings of the Phase 3 ASPEN trial.

While preliminary results were publicly shared last year and widely discussed at the 2023 Bronchiectasis World Conference in Dundee, Scotland, the news has now reached a significant milestone: the findings have been formally published in The New England Journal of Medicine — one of the most respected and influential medical journals in the world.

I knew this publication was on the horizon. Dr. Chuck Daley, a key voice in bronchiectasis care and research, has referenced it in multiple recent talks. Seeing it in print is a powerful moment — not just for him and the incredible research teams involved, but for all of us living with the daily challenges of bronchiectasis. It represents hope, validation, and real scientific momentum.

As always, let’s stay the course while we wait for what may come next. That means keeping our weight in a healthy range, choosing nutrient-rich foods, doing our daily airway clearance, exercising regularly, managing GERD, and just as importantly — having faith, staying connected, and taking deep breaths when we need to. Because now more than ever, it feels like help is on the way.